Lexicon Pharmaceuticals, Inc. (LXRX): Total Liabilities
$77.45M
As of 2025-12-31
$75.53M
As of 2026-06-30
+0.1%
3-year compound annual growth
+10.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $77.45M | -49.2% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $152.47M | +11.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $136.32M | +76.6% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $77.17M | +231.0% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $23.31M | -50.8% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $47.42M | -84.2% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $300.61M | -3.2% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $310.54M | -15.7% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $368.27M | n/c | 2019-03-15, Balance as of period end |
| 2016-12-31 | $318.22M | -13.1% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $366.11M | +95.4% | 2017-03-06, Balance as of period end |
| 2014-12-31 | $187.36M | +80.2% | 2016-03-11, Balance as of period end |
| 2013-12-31 | $104.00M | -1.0% | 2015-03-12, Balance as of period end |
| 2012-12-31 | $105.10M | -20.9% | 2014-03-07, Balance as of period end |
| 2011-12-31 | $132.94M | +10.9% | 2013-03-11, Balance as of period end |
| 2010-12-31 | $119.86M | n/a | 2012-03-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $153.75M | +7.8% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.76M | -77.2% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $104.11M | -14.8% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
Compare LXRX, GOSS, OCUL, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗